Beijing Health (Holdings) Valuation

Is 2389 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2389 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2389's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2389's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2389?

Key metric: As 2389 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2389. This is calculated by dividing 2389's market cap by their current revenue.
What is 2389's PS Ratio?
PS Ratio	3.4x
Sales	HK$135.62m
Market Cap	HK$466.53m

2389 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	-2.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 2389's PS Ratio compare to its peers?

The above table shows the PS ratio for 2389 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.8x
8037 China Biotech Services Holdings	6.9x	n/a	HK$429.3m
286 Aidigong Maternal & Child Health	0.7x	n/a	HK$344.0m
1419 Human Health Holdings	0.5x	n/a	HK$296.1m
2293 Bamboos Health Care Holdings	2.9x	n/a	HK$257.6m
2389 Beijing Health (Holdings)	3.4x	n/a	HK$466.5m

Price-To-Sales vs Peers: 2389 is expensive based on its Price-To-Sales Ratio (3.4x) compared to the peer average (2.7x).

Price to Sales Ratio vs Industry

How does 2389's PS Ratio compare vs other companies in the HK Healthcare Industry?

10 Companies	Price / Sales	Estimated Growth	Market Cap
1099 Sinopharm Group	0.1x	5.8%	US$8.20b
9885 YSB	0.2x	n/a	US$535.45m
2289 Charmacy Pharmaceutical	0.2x	n/a	US$131.55m
9955 ClouDr Group	0.2x	23.5%	US$92.79m

10 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 2389 is expensive based on its Price-To-Sales Ratio (3.4x) compared to the Hong Kong Healthcare industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is 2389's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2389 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 2389's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sinopharm Group

HK$63.8b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.75

-2.6%

9.2%

OrbusNeich Medical Group Holdings

HK$3.3b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

6929

HK$3.80

-7.8%

-46.5%

Sisram Medical

HK$1.6b

Engages in the research, design, development, manufacture, and sales of medical aesthetics and dental equipment, home use devices, injectables, and cosmeceuticals products in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa.

1696

HK$3.46

3.6%

-35.6%